Clinical trial readout dates for Viking Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is July 2027.
| Phase 3 VK2735 Weight Loss · NCT07104500 | July 2027 Ongoing |
| Phase 3 VK2735 Weight Loss · NCT07104383 | July 2027 Ongoing |
| Phase 3 VK2735 Weight Loss · NCT07868835 | July 2028 Recruiting |
| Phase 3 VK2735 Oral Weight Loss · NCT07868939 | October 2028 Recruiting |
Viking Therapeutics Inc. reported $960M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $183M; at that rate the cash would last about 5 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-28 |